Update shared on26 Sep 2025
Fair value Decreased 50%The consensus analyst price target for Polarean Imaging has been halved, reflecting downward revisions driven by declining profitability and a lower future P/E, resulting in a new fair value estimate of £0.04.
What's in the News
- Polarean Imaging submitted a new Phase III clinical trial protocol to the FDA to expand XENOVIEW's indication to include quantitative gas-exchange imaging.
- The company has requested FDA feedback through a Type C meeting to align on the Phase III study design, with FDA review expected by fourth quarter 2025.
- The trial will assess XENOVIEW’s safety and diagnostic performance in evaluating pulmonary function versus current standard tests.
- If approved, the expanded indication would broaden XENOVIEW’s clinical use by allowing non-invasive visualization and quantification of gas-exchange abnormalities in various lung diseases.
Valuation Changes
Summary of Valuation Changes for Polarean Imaging
- The Consensus Analyst Price Target has significantly fallen from £0.08 to £0.04.
- The Future P/E for Polarean Imaging has significantly fallen from 86.88x to 46.63x.
- The Net Profit Margin for Polarean Imaging has significantly fallen from 10.73% to 8.43%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.